Quick Answer
Syndax Pharmaceuticals Inc reported Research And Development Expense of $258.78 million for the year ending 2025.
- Syndax Pharmaceuticals Inc showed an increase of +7.1% in Research And Development Expense from 2024 to 2025.
- This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Syndax Pharmaceuticals Inc's Research And Development Expense has grown by 2,443.3%.
- Historical annual values: Fiscal year 2025: $258.78 million | Fiscal year 2024: $241.65 million | Fiscal year 2023: $163.03 million | Fiscal year 2022: $118.50 million | Fiscal year 2021: $88.25 million | Fiscal year 2020: $50.44 million | Fiscal year 2019: $42.99 million | Fiscal year 2018: $60.11 million | Fiscal year 2017: $48.20 million | Fiscal year 2016: $31.67 million | Fiscal year 2015: $9.55 million | Fiscal year 2014: $10.18 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: